Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience

Pharmacogenomics. 2020 Apr;21(6):375-386. doi: 10.2217/pgs-2020-0007. Epub 2020 Feb 20.


In recent years, the genomics community has witnessed the growth of large research biobanks, which collect DNA samples for research purposes. Depending on how and where the samples are genotyped, biobanks also offer the potential opportunity to return actionable genomic results to the clinical setting. We developed a preemptive clinical pharmacogenomic implementation initiative via a health system-wide research biobank at the University of Colorado. Here, we describe how preemptive return of clinical pharmacogenomic results via a research biobank is feasible, particularly when coupled with strong institutional support to maximize the impact and efficiency of biobank resources, a multidisciplinary implementation team, automated clinical decision support tools, and proactive strategies to engage stakeholders early in the clinical decision support tool development process.

Keywords: biobank; implementation; personalized medicine; pharmacogenetics; pharmacogenomics; precision medicine.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Academic Medical Centers / methods
  • Academic Medical Centers / trends*
  • Biological Specimen Banks / trends*
  • Colorado / epidemiology
  • Cytochrome P-450 CYP2C19 / genetics
  • Decision Support Systems, Clinical / trends*
  • Humans
  • Pharmacogenetics / methods
  • Pharmacogenetics / trends*
  • Precision Medicine / methods
  • Precision Medicine / trends*


  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19